(Q43651276)

25 November 2017

title

Personal view: to treat or not to treat? Helicobacter pylori and gastro-oesophageal reflux disease - an alternative hypothesis (English)

1 reference

25 November 2017

1 reference

Axon AT

1

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

Alimentary Pharmacology & Therapeutics

25 November 2017

published in

1 reference

25 November 2017

volume

19

1 reference

25 November 2017

issue

3

1 reference

25 November 2017

page(s)

253-261

1 reference

Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01847.X

Helicobacter pylori and gastric diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01847.X

Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01847.X

Changing patterns in the incidence of esophageal and gastric carcinoma in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01847.X

Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01847.X

The significance of cagA(+) Helicobacter pylori in reflux oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01847.X

Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease -- results from a randomized trial programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01847.X

Active and inactive gastroesophageal reflux diseases related to Helicobacter pylori therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01847.X

Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01847.X

Rates of dyspepsia one year after Helicobacter pylori screening and eradication in a Danish population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01847.X

Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Leeds HELP Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01847.X

Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01847.X

Helicobacter pylori infection in childhood: risk factors and effect on growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01847.X

Growth slowing after acute Helicobacter pylori infection is age-dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01847.X

Height and risk of death among men and women: aetiological implications of associations with cardiorespiratory disease and cancer mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01847.X

Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01847.X

Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01847.X

Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01847.X

Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01847.X

Treatment with a proton pump inhibitor promotes corpus gastritis in patients with Helicobacter pylori-infected antrum-predominant gastritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01847.X

Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01847.X

Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01847.X

Helicobacter pylori infection and the development of gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01847.X

Long-term Symptom Patterns, Endoscopic Findings, and Gastric Histology in Helicobacter pylori-Infected and -Uninfected Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01847.X

Heartburn treatment in primary care: randomised, double blind study for 8 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01847.X

Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.01847.X

10.1111/J.1365-2036.2004.01847.X

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference